Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin's Lymphoma

Interventions: Drug: Fenretinide
Drug: Cytarabine
Drug: Methotrexate

First Posted Date: 2010-08-24

Last Posted Date: 2022-03-31

Lead Sponsor: South Plains Oncology Consortium

Target Recruit Count: 3

Registration Number: NCT01187810

Locations: 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Phase 1

Terminated

Conditions: Lymphoblastic Leukemia, Acute
Leukemia, Lymphoblastic, Acute
Lymphoblastic Leukemia, Acute, Childhood
Leukemia, Lymphoblastic, Acute, T Cell

Interventions: Drug: EZN-3042
Drug: Cytarabine
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine
Drug: PEG-asparaginase
Drug: Methotrexate
Drug: Hydrocortisone

First Posted Date: 2010-08-23

Last Posted Date: 2024-02-01

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 6

Registration Number: NCT01186328

Locations: 🇦🇺
Sydney Children's Hospital, Sydney, Australia
🇺🇸
St. Jude, Memphis, Tennessee, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States

and more 4 locations

Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)

Not Applicable

Completed

Conditions: AML

Interventions: Drug: Sirolimus
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2010-08-19

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 36

Registration Number: NCT01184898

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine

Phase 2

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Cytarabine
Drug: Idarubicin
Drug: Etoposide
Drug: Azacitidine
Drug: Lenograstim

First Posted Date: 2010-08-12

Last Posted Date: 2020-12-31

Lead Sponsor: University of Ulm

Target Recruit Count: 277

Registration Number: NCT01180322

Locations: 🇦🇹
Universitätsklinikum Innsbruck, Innsbruck, Austria
🇩🇪
Universitätsklinikum Schleswig-Holstein, Kiel, Germany
🇦🇹
Krankenhaus der Barmherzigen Schwestern, Linz, Austria

and more 40 locations

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: midostaurin
Drug: Bortezomib
Drug: mitoxantrone hydrochloride
Drug: etoposide
Drug: cytarabine

First Posted Date: 2010-08-04

Last Posted Date: 2016-07-06

Lead Sponsor: Alison Walker

Target Recruit Count: 34

Registration Number: NCT01174888

Locations: 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States

Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Granulocyte colony-stimulating factor (G-CSF)
Drug: Cladribine
Drug: Cytarabine
Drug: All-Trans Retinoic Acid (ATRA)
Drug: Midostaurin

First Posted Date: 2010-07-13

Last Posted Date: 2013-07-23

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 11

Registration Number: NCT01161550

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia

Not Applicable

Completed

Conditions: Leukemia

First Posted Date: 2010-07-05

Last Posted Date: 2021-09-13

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 76

Registration Number: NCT01156883

Locations: 🇮🇹
Azienda Ospedaliera - Nuovo Ospedale "Torrette", Ancona, Italy
🇮🇹
USL 8 - Ospedale S.Donato, Arezzo, Italy
🇮🇹
UO Ematologia con trapianto- AOU Policlinico Consorziale di Bari, Bari, Italy

and more 40 locations

Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: cytarabine
Drug: etoposide
Drug: everolimus
Drug: idarubicin
Drug: mitoxantrone hydrochloride

First Posted Date: 2010-06-30

Last Posted Date: 2022-10-26

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 11

Registration Number: NCT01154439

Locations: 🇮🇹
Università La Sapienza, Roma, Italy
🇮🇹
Azienda Ospedaliera Universitaria - Università degli Studi di Napoli "Federico II" - Facoltà di Medicina e Chirurgia, Napoli, Italy
🇮🇹
Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy

and more 2 locations

Autologous Transplant in HIV Patients (BMT CTN 0803)

Phase 2

Completed

Conditions: HIV
Lymphoma

Interventions: Procedure: Autologous transplant
Drug: BCNU
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan

First Posted Date: 2010-06-10

Last Posted Date: 2023-01-04

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 43

Registration Number: NCT01141712

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
University of CA, SF, San Francisco, California, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 13 locations

Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA
Secondary Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
de Novo Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL
Alkylating Agent-Related Acute Myeloid Leukemia
Previously Treated Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: Lenalidomide
Drug: Cytarabine
Drug: Idarubicin
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-05-28

Last Posted Date: 2014-12-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 61

Registration Number: NCT01132586

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy